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Cervical cancerFOXM1 is a well-established oncogenic factor that has been reported to be involved in multiple bio-
logical processes including cell proliferation, growth, angiogenesis, migration and invasion. It can
also be regulated by miRNAs. In this study, we reported that FOXM1 is directly targeted by miR-
342-3p, which is down-regulated along with its host gene, EVL, in human cervical cancer tissues
compared to the adjacent normal tissues. Functional studies suggested that the overexpression of
miR-342-3p inhibits cell proliferation, migration and invasion in cervical cell lines. FOXM1 is upreg-
ulated and negatively correlates with miR-342-3p in cervical cancer tissues, and the overexpression
of FOXM1 rescues the phenotype changes induced by the overexpression of miR-342-3p.
 2014 Published by Elsevier B.V. on behalf of the Federation of European Biochemical Societies.1. Introduction
Mammalian transcription factor Forkhead Box M1 (FOXM1)
belongs to the extensive family of Forkhead transcription factors,
whose members harbor 100 amino acids and an evolutionarily
conserved DNA binding domain called Forkhead or winged-helix
domain [1,2]. Genome-wide gene expression proﬁles of cancer
have shown that FOXM1 is commonly upregulated in a diverse
array of human solid tumors, including liver, lung, colon, pancre-
atic, brain, breast, genital system (prostate, cervical and ovarian
tumors), as well as hematological and nervous system tumors
[3,4]. It is demonstrated that FOXM1 is involved in cell prolifera-
tion, cell cycle progression, apoptosis, cell differentiation, and angi-
ogenesis, and plays an essential role in the invasion, metastasis,
and epithelial–mesenchymal transitions in cancer [5]. Moreover,
FOXM1 has been reported to be regulated by miRNAs, for example,
miR-134 in lung cancer [6] and miR-370 in acute myeloid leukemia
[7].
MicroRNAs (miRNAs) are ubiquitous, 22-nucleotide (nt), non-
coding regulators that modulate essential cellular processes at thepost-transcriptional level [8]. Accumulating evidence suggests that
aberrantly expressed miRNAs lead to various diseases, including
cancer [9]. Among them, cervical cancer is a primary cancer in
females with a high incidence all over the world [10]. It is reported
that a number of miRNAs are aberrantly expressed in cervical can-
cer. miR-21 is overexpressed in cervical cancer and is a negative
regulator of expression of the tumor suppressor gene programmed
cell death 4 (PDCD4) [11]. miR-19a and miR-19b are overexpressed
in cervical cancer cells and enhance cell growth and invasion by
targeting Cullin 5 (CUL5) [12]. Both miRNAs act as onco-miRNAs.
However, some tumor suppressor miRNAs were also studied in
cervical cancer. For example, miR-506 exerts its anti-proliferative
function by directly targeting Gli3 and acts as a tumor suppressor
by inhibiting cervical cancer growth in vitro and in vivo [13].
Expression of hsa-miR-342, a microRNA encoded in an intron of
the gene EVL, is commonly suppressed in human colorectal cancer
(CRC) [14]. miR-342 is involved in the regulation of DNA methyl-
transferase 1 (DNMT1) to inhibit CRC cell proliferation and metas-
tasis both in vitro and in vivo [15].
A large cohort of studies provided evidence for the pivotal role
of FOXM1 in the regulation of cell proliferation, migration, and
invasion, as well as metastasis in various cancers. However, evi-
dence of a biological association between FOXM1 and miR-342-
3p in cervical cancer has not been reported. In the present study,
we found that FOXM1 was directly targeted by miR-342-3p. In
Table 1
Patient clinical information.
Index Gender Age Clinical diagnosis
1 Female 50 CIN I
2 Female 46 CIN I
3 Female 43 CIN I
4 Female 44 CIN I
5 Female 28 CIN I
6 Female 41 CIN I
7 Female 33 CIN I
8 Female 41 CIN I
9 Female 27 CIN I
10 Female 48 CIN I
11 Female 52 CIN I
12 Female 40 CIN I
13 Female 35 CIN I
14 Female 29 CIN I
15 Female 56 CIN I
16 Female 50 CIN I
17 Female 47 CIN I
18 Female 42 CIN I
19 Female 65 CIN I
20 Female 46 CIN I
21 Female 52 CIN I
22 Female 47 CIN I
23 Female 41 CIN I
24 Female 28 CIN I
25 Female 36 CIN I
26 Female 40 CIN I
27 Female 42 CIN I
28 Female 45 CIN I
29 Female 49 CIN I
30 Female 54 CIN I
31 Female 36 CIN I
32 Female 35 CIN I
33 Female 30 CIN I
34 Female 54 CIN I
35 Female 50 CIN I
36 Female 68 CIN II
37 Female 32 CIN II
38 Female 35 CIN II
39 Female 34 CIN II
40 Female 29 CIN II
41 Female 41 CIN II
42 Female 43 CIN II
43 Female 47 CIN II
44 Female 37 CIN II
45 Female 43 CIN II
46 Female 40 CIN II
47 Female 39 CIN II
48 Female 39 CIN II
49 Female 33 CIN II
50 Female 36 CIN II
51 Female 24 CIN II
52 Female 34 CIN II
53 Female 41 CIN II
54 Female 40 CIN II
55 Female 35 CIN II
56 Female 33 CIN II
57 Female 28 CIN II
58 Female 42 CIN II
59 Female 46 CIN II
60 Female 39 CIN II
61 Female 30 CIN II
62 Female 41 CIN II
63 Female 55 CIN II
64 Female 45 CIN II
65 Female 41 CIN II
66 Female 36 CIN II
67 Female 33 CIN II
68 Female 38 CIN II
69 Female 23 CIN II
70 Female 29 CIN II
71 Female 35 CIN III
72 Female 23 CIN III
73 Female 44 CIN III
74 Female 45 CIN III
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lated in cervical intraepithelial neoplasia (CIN) tissues, especially
in cervical cancer tissues. Moreover, the overexpression of miR-
342-3p mimics suppressed cell growth in vitro and in vivo and also
inhibits the migration and invasion of the HeLa and C33A cell lines.
Restoration of FOXM1 abolished the suppression of proliferation,
migration and invasion induced by miR-342-3p mimics in cervical
cancer cell lines.
2. Materials and methods
2.1. Cell culture and transfection
The human cervical cancer cell lines are maintained in the fol-
lowing medium: HeLa and Caski in RPMI1640 (GIBCO, USA), and
C33A and Siha in Eagle’s Minimum Essential Medium (GIBCO,
USA) supplemented with 10% fetal bovine serum (FBS), 100 IU/ml
of penicillin and 100 lg/ml of streptomycin. The cell lines were
incubated at 37 C in a humidiﬁed chamber supplemented with
5% CO2. Transfection was performed with Lipofectamine 2000
Reagent (Invitrogen) following the manufacturer’s protocol.
2.2. Clinical tumor specimens
Twenty-seven pairs of cervical cancer samples and matched
normal cervical tissues as well as CIN tissues (CIN I: 35 samples;
CIN II: 35 samples; and CIN III: 45 samples) were collected from
2012 to 2014 in Qingdao Haici Hospital. Among them, pathological
analysis conﬁrmed that the cancer tissues are human cervical
squamous cancer (low-differentiation: 9 samples; mid-differentia-
tion: 13 samples; and high-differentiation: 5 samples). All of the
samples were obtained with the patients’ informed consent and
approved by the Ethics Committee of Qingdao Haici Hospital. The
patient clinical information is shown in Table 1. The category of
cervical samples was conﬁrmed by pathological analysis. The
RNA from tissue samples was isolated using a miRVana™ miRNA
Isolation Kit (Ambion) following the manufacturer’s instructions.
2.3. Luciferase reporter assay
For luciferase reporter experiments, HeLa and C33A cells were
seeded at 1.5  105 cells per well in a 24-well plate and were co-
transfected 24 h later with pGL3-control (400 ng), wild-type
pGL3-FOXM1 (400 ng), mutant pGL3-FOXM1 (400 ng), pGL4.73
vector (50 ng; Promega) and miR-342-3p mimics (50 nM) or nega-
tive control miRNA (scramble, 50 nM) using Lipofectamine 2000
(Invitrogen). The cells were harvested 48 h after transfection, and
ﬁreﬂy and Renilla luciferase activities were analyzed with the
Dual-Luciferase Reporter Assay System according to the manufac-
turer’s instructions (Promega).
2.4. Western blot and immunohistochemistry assays
Total cellular proteins were extracted and separated by SDS–
PAGE gels, and Western blot analysis was performed according to
standard procedures. b-Actin on the same membrane was used
as a loading control. The primary antibodies included mono-clonal
anti-FOXM1 (1:2000, Abcam) and anti-GAPDH (1:5000, Abcam).
Proteins were visualized using the ECL procedure (Amersham Bio-
sciences, Sweden). The bands of gray intensity were analyzed by
Image J. IHC was performed according to the methods described
previously (1). After pretreatment with a microwave, the sections
were blocked and incubated using monoclonal mouse anti-FOXM1
(Abcam). The staining intensity was assessed.(continued on next page)
Table 1 (continued)
Index Gender Age Clinical diagnosis
75 Female 44 CIN III
76 Female 38 CIN III
77 Female 46 CIN III
78 Female 61 CIN III
79 Female 39 CIN III
80 Female 32 CIN III
81 Female 46 CIN III
82 Female 33 CIN III
83 Female 48 CIN III
84 Female 55 CIN III
85 Female 37 CIN III
86 Female 27 CIN III
87 Female 29 CIN III
88 Female 40 CIN III
89 Female 46 CIN III
90 Female 40 CIN III
91 Female 37 CIN III
92 Female 40 CIN III
93 Female 45 CIN III
94 Female 50 CIN III
95 Female 25 CIN III
96 Female 39 CIN III
97 Female 37 CIN III
98 Female 32 CIN III
99 Female 43 CIN III
100 Female 47 CIN III
101 Female 47 CIN III
102 Female 38 CIN III
103 Female 37 CIN III
104 Female 47 CIN III
105 Female 38 CIN III
106 Female 40 CIN III
107 Female 50 CIN III
108 Female 53 CIN III
109 Female 38 CIN III
110 Female 36 CIN III
111 Female 31 CIN III
112 Female 69 CIN III
113 Female 64 CIN III
114 Female 42 CIN III
115 Female 50 CIN III
116 Female 38 Cervical squamous cancer
117 Female 47 Cervical squamous cancer
118 Female 48 Cervical squamous cancer
119 Female 62 Cervical squamous cancer
120 Female 34 Cervical squamous cancer
121 Female 46 Cervical squamous cancer
122 Female 40 Cervical squamous cancer
123 Female 69 Cervical squamous cancer
124 Female 49 Cervical squamous cancer
125 Female 38 Cervical squamous cancer
126 Female 42 Cervical squamous cancer
127 Female 34 Cervical squamous cancer
128 Female 41 Cervical squamous cancer
129 Female 37 Cervical squamous cancer
130 Female 55 Cervical squamous cancer
131 Female 50 Cervical squamous cancer
132 Female 43 Cervical squamous cancer
133 Female 66 Cervical squamous cancer
134 Female 41 Cervical squamous cancer
135 Female 46 Cervical squamous cancer
136 Female 46 Cervical squamous cancer
137 Female 52 Cervical squamous cancer
138 Female 63 Cervical squamous cancer
139 Female 48 Cervical squamous cancer
140 Female 43 Cervical squamous cancer
141 Female 68 Cervical squamous cancer
142 Female 58 Cervical squamous cancer
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The 3-(4,5-dimethylthiazole-2-yl)-2,5-biphenyl tetrazolium
bromide (MTT) assay was used to evaluate cell viability andproliferation. The spectrophotometric absorbance of each sample
was measured at 570 nm. All experiments were performed in trip-
licate, and the average results were calculated. For the colony for-
mation assay, tumor cells (200 cells per well in a 12-well plate)
overexpressing miR-342-3p mimics or scramble were seeded in
complete medium. The cells were grown for 10 days at 37 C with
5% CO2. Colony formation was visualized with crystal violet stain-
ing. The number of colonies with more than 50 cells were counted.
2.6. Migration and invasion assays
For the transwell migration assays, 6  104 HeLa cells and
10  104 C33A cells were plated in the top chamber with a non-
coated membrane (24-well insert; 8-lm pore size; BD Biosci-
ences). For the invasion assays, 1  105 HeLa cells and 2  105
C33A cells were plated in the top chamber with a Matrigel-coated
membrane (24-well insert; 8-lm pore size; BD Biosciences). For
both assays, the cells were plated in serum-free medium, and med-
ium supplemented with 20% serum (GIBCO) was used as a chemo-
attractant in the lower chamber. The cells were incubated for 16 h
at 37 C and 5% CO2 in a tissue culture incubator. After 16 h, the
non-migrated/non-invaded cells were removed from the upper
sides of the transwell membrane ﬁlter inserts using cotton-tipped
swabs. The migrated/invaded cells on the lower sides of the inserts
were stained with crystal violet, and ﬁve random ﬁelds of the cells
were counted.
2.7. Xenograft experiments
Equal numbers of HeLa cells (106) with forced expression of
miR-342-3p mimics or scramble were suspended in 100 ll PBS
and injected subcutaneously into the right rear ﬂank of each mouse
(5 mice per group). Tumor growth was monitored every 2 days in
each group. The tumor volume was calculated using the formula
V = 1/2 a  b2, where a is the longest tumor axis and b is the short-
est tumor axis. The mice were sacriﬁced 20 days later.
2.8. Statistical analysis
SPSS 17.0 software was used for the statistical analysis. The data
are presented as the mean and standard deviation (s.d.). Group
comparisons were performed using Student’s t-test. Differences
were considered signiﬁcant at P < 0.05.
3. Results
3.1. miR-342-3p is down-regulated in cervical cancer tissue and cell
lines
To elucidate the role of miR-342-3p in human cervical cancer
development, we detected expression levels of miR-342-3p and
its host gene, EVL, in 27 cervical cancer tissue samples and paired
adjacent normal tissue samples by qRT-PCR. As shown in Fig. 1A
and B, the expression levels of the EVL mRNA and miR-342-3p
were generally reduced in cervical cancer tissues compared to
those in adjacent normal tissues. To further study whether the
downregulation of miR-342-3p and its host gene, EVL mRNA, is
speciﬁc to cervical cancer, we used qRT-PCR to analyze their
expression levels in cervical intraepithelial neoplasia (CIN) samples
(CIN I: 35 samples; CIN II: 35 samples; and CIN III: 45 samples) and
cervical cancer samples. The data showed that the expression lev-
els of EVL mRNA and miR-342-3p were both relatively reduced in
the CIN tissues, irrespective of the grade, but the levels were much
lower in cervical cancer tissues than those in the CIN tissues
(Fig. 1C and D). Subsequently, we assessed the expression levels
Fig. 1. miR-342-3p and its host gene, EVL, are generally down-regulated in human cervical cancer tissues and cell lines. The expression levels of miR-342-3p (B) and its host
gene EVL (A) were analyzed by qRT-PCR with human CIN samples (CIN I: 35 samples; CIN II: 35 samples; and CIN III: 45 samples) and cervical cancer tissues (27 samples). The
levels of miR-342-3p and EVL mRNA were lower in cervical cancer tissues than in CIN tissues, although their levels in CIN tissues (grade I–III) were relatively low (C and D).
The expression of two RNAs was relatively down-regulated in the HeLa, C33A, Siha and Caski cell lines by qRT-PCR (E). ⁄P < 0.05. The experiments were performed in
triplicate.
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cell lines: HeLa, C33A, Siha and Caski. We used the relative expres-
sion levels of EVL mRNA and miR-342-3p of the respective loading
controls in the four cell lines due to the lack of a normal cervical
cell line. Although the degree of downregulation varied from one
cell line to another, their expression was relatively low overall.As the potential of downregulation is greater in the HeLa and
C33A cell lines than that in the Siha and Caski cell lines (Fig. 1E),
further studies were performed in the HeLa and C33A cell lines.
These data indicate that miR-342-3p and its host gene, EVL mRNA,
are down-regulated in CIN and cervical cancer tissues, as well as in
cervical cell lines.
Fig. 2. miR-342-3p directly targets FOXM1. (A) The miR-342-3p binding sites located on the FOXM1 mRNA 30UTR. (B) miR-342-3p or scramble and wild-type or mutant
FOXM1 30UTR were co-transfected into HeLa cells. miR-342-3p reduced the luciferase activities with wild-type FOXM1 30UTR and did not alter the luciferase activities with
mutant FOXM1 30UTR. (C) miR-342-3p decreased endogenous FOXM1 mRNA expression in HeLa and C33A cells. (D) Western blot assays showed that the expression of
FOXM1 protein was up-regulated in HeLa and C33A cells and down-regulated in Siha and Caski cells. (E) Western blot was used to detect the expression of FOXM1 protein in
HeLa cells by ectopic expression of miR-342-3p and in Siha cells by blocking miR-342-3p. GAPDH is a loading control. ⁄P < 0.05. The experiments were performed in triplicate.
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FOXM1 has been reported to be an important molecule that
triggers metastasis and invasion in various cancers. Using predic-
tion tools, we predicted that the target miRNA of FOXM1 was
miR-342-3p. To further conﬁrm that miR-342-3p directly targets
oncogene FOXM1, we performed luciferase reporter assays toexamine whether miR-342-3p interacts directly with its target
oncogenic FOXM1. We identiﬁed a putative binding site of miR-
342-3p in the FOXM1 mRNA 30UTR (Fig. 2A). The fragments were
then cloned downstream of the luciferase gene with a stop codon
in the pGL3-control vector. Subsequently, after validation of the
miR-342-3p mimics in the HeLa and C33A cell lines (Fig. 4A and
B), we performed the luciferase assay in HeLa cells. As shown in
X.-r. Li et al. / FEBS Letters 588 (2014) 3298–3307 3303Fig. 2B, the reporter with the wild-type 30UTR of FOXM1 showed
markedly lower luciferase activity in HeLa cells expressing miR-
342-3p mimics compared with those expressing negative control
miRNA; however, the reduced luciferase activity caused by the
wild-type FOXM1 mRNA 30UTR was abolished by mutant 30UTR.
To further validate the association between miR-342-3p and
FOXM1, we detected endogenous FOXM1 mRNA in the HeLa and
C33A cell lines transfected with miR-342-3p mimics or a non-spe-
ciﬁc miRNA (as a negative control). qRT-PCR showed that miR-342-
3p mimics dramatically decreased the expression of endogenous
FOXM1 mRNA (Fig. 2C). Next, western blots analyzed the protein
level of FOXM1 in the four cervical lines: HeLa, C33A, Siha, and
Caski. As shown in Fig. 2D, the protein levels in the HeLa and
C33A lines were higher than those in the Siha and Caski lines. Thus,
HeLa cells transfected with miR-342-3p mimics and Siha cellsFig. 3. miR-342-3p suppressed proliferation and growth in vitro and in vivo. Ectopic ex
(A and B) and colony formation assays (C and D) in HeLa and C33A cells. Xenograft ex
in vivo. The experiments were performed in triplicate. Each group (5 mice) was inject
experiments were performed in triplicate.transfected with anti-sense oligomer of miR-342-3p (anti-miR-
342-3p) were adopted. Western blots showed that the expression
of FOXM1 protein was decreased by approximately 70% in HeLa
cells transfected with miR-342-3p mimics and that the FOXM1
protein level was higher in Siha cells transfected with anti-miR-
342-3p compared with the control group cells. Taken together,
these results suggest that FOXM1 is a direct target gene of miR-
342-3p.
3.3. miR-342-3p suppresses proliferation, growth, invasion and
migration of human cervical cells
To investigate the roles of miR-342-3p in cervical cancer cells,
MTT assays and colony formation assays were used to evaluate
whether miR-342-3p affects cell viability and growth. Overexpres-pression of miR-342-3p suppressed cell viability, proliferation and growth by MTT
periments were performed to conﬁrm the effects of miR-342-3p on tumor growth
ed with HeLa cells overexpressing miR-342-3p mimics or scramble. ⁄P < 0.05. The
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24 h and 48 h after transfection and growth 10 days after seeding
compared with the scramble group cells in the HeLa and C33A cell
lines (Fig. 3A–D). Furthermore, to determine whether miR-342-3p
is involved in tumorigenesis in vivo, a xenograft tumor model was
used in the severe combined immunodeﬁciency (SCID) mice.
Because miR-342-3p is down-regulated in cervical cancer cells,
miR-342-3p mimics were used to generate a gain-of-function
model. Human cervical HeLa cells transfected with miR-342-3p
mimics or the control oligomers were injected into 5 nude mice.
As a result, the volume of the tumors derived from the miR-342-
3p mimic-treated HeLa cells was dramatically reduced at 8, 12,
16, and 20 days compared to the control group (Fig. 3E and F).
The result is consistent with the effects of miR-342-3p on cultured
cervical cancer cells in vitro, which indicates that miR-342-3p
inhibits cell growth in vitro and in vivo.
In addition, we analyzed the effects of miR-342-3p on cell inva-
sion and migration in the HeLa and C33A cell lines. Forced expres-
sion of miR-342-3p mimics suppressed invasion by more than 60%
in HeLa cells and by more than 50% in C33A cells (Fig. 4C and D).
Simultaneously, we evaluated the inﬂuence of miR-342-3p on cell
migration. As shown in Fig. 4E and F, overexpression of miR-342-Fig. 4. miR-342-3p suppressed the invasion and migration of HeLa and C33A cells. (A a
Ectopic expression of miR-342-3p suppressed cell invasion and migration in HeLa and C3p suppressed migration by more than 50% in the above two cell
lines. These results indicated that miR-342-3p acts as a tumor
suppressor in human cervical cells.
3.4. FOXM1 can rescue the phenotypes caused by miR-342-3p
It is reported that FOXM1 plays critical roles in cell growth,
metastasis and invasion in various types of cancers, and it can be
regulated by miRNAs. To study whether miR-342-3p functions
through FOXM1, we constructed FOXM1 expression plasmids
without the 30UTR (pCMV6/FOXM1), which cannot be disrupted
by miR-342-3p, to perform a rescue experiment. Western blotting
analysis showed that overexpression of FOXM1 can restore the
protein level decreased by miR-342-3p mimics (Fig. 5B). Further-
more, MTT and colony formation assays and invasion and migra-
tion assays were employed in HeLa and C33A cells co-transfected
with miR-342-3p mimics and pCMV6/FOXM1 or their control olig-
omers and vectors. Restoration of FOXM1 abolished the cell viabil-
ity, colony formation rate, invasion and migration reduced by miR-
342-3p mimics (Fig. 5C–F). These results showed that FOXM1 is a
direct function target gene of miR-342-3p and that miR-342-3p
functions as a tumor suppressor through FOXM1.nd B) miR-342-3p mimics were validated effectively in HeLa and C33A cells. (C–E)
33A cells. ⁄P < 0.05. The experiments were performed in triplicate.
Fig. 5. FOXM1 abolished the suppression induced by miR-342-3p mimics. (A) qRT-PCR was used to analyze the expression of miR-342-3p in each group of the transfected
cells. (B) Western blot assays conﬁrmed that restoration of FOXM1 could rescue its downregulation caused by miR-342-3p mimics. (C–F) Forced expression of FOXM1 rescued
the suppression effects on cell proliferation, growth, invasion and migration by MTT, colony formation assays and migration and invasion assays. ⁄P < 0.05. The experiments
were performed in triplicate.
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Fig. 6. miR-342-3p and its host gene, EVL, were negatively correlated with FOXM1 expression in CIN and cervical cancer tissues. (A) qRT-PCR was used to analyze the
expression of FOXM1mRNA, which is up-regulated in HeLa, C33A, Siha and Caski cell lines. (B and C) miR-342-3p and EVL were negatively correlated with FOXM1 by qRT-PCR
in 27 cervical cancer tissue samples. U6 snRNA and GAPDH were used as inner controls. (D) A model of miR-342-3p function. miR-342-3p is an intronic RNA of EVL primary
transcripts. (E) The expression of FOXM1 varied with the progression of CIN and was dramatically elevated in cervical cancer tissues by IHC. ⁄P < 0.05. The experiments were
performed in triplicate.
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cervical cancer tissues
To further elucidate the association between FOXM1 and miR-
342-3p, qRT-PCR was used to detect the level of FOXM1 mRNA in
HeLa, C33A, Siha and Caski cell lines and 27 pairs of cervical cancer
tissues and adjacent normal tissues. The levels of FOXM1 mRNA in
the four cervical cell lines were relatively higher than those in nor-
mal cervical tissues, although the degrees varied from more than
2- to 7-fold (Fig. 6A). As shown in Fig. 6B, the expression of FOXM1
was upregulated in cervical cancer tissues compared with that in
adjacent normal tissues, and FOXM1 and miR-342-3p had a nega-
tive correlation. Moreover, we detected the expression of the host
gene EVL by qRT-PCR. The data showed that EVL was negatively
correlated with FOXM1, although the correlation was not statisti-
cally signiﬁcant (Fig. 6C). In addition, we performed immunohisto-
chemistry to analyze the expression of FOXM1 protein. As shown
in Fig. 6E, the levels of FOXM1 protein were higher in CIN and cer-
vical cancer tissues than those in normal cervical tissues, and the
expression of FOXM1 varied in response to human cervical malig-
nancy (Fig. 6E). These data indicated that FOXM1 is up-regulatedby miR-342-3p and thus functions as an oncogene in human cervi-
cal cancer tissues and cell lines.
4. Discussion
FOXM1 is a famous transcription factor that is involved in mul-
tiple biological processes, including cancer. The increased expres-
sion of FOXM1 has been detected in diverse cancer cell lines and
cancer tissues, indicating that FOXM1 is critical for tumor cell pro-
liferation and growth [16,17]. Elevated expression of FOXM1 is
associated with tumor malignancy. A large amount of evidence
suggests that FOXM1 contributes to oncogenesis [2]. The increased
expression of FOXM1 promotes angiogenesis [18], invasion and
metastasis [19]. In pancreatic cancer cells, downregulation of
FOXM1 expression has reduced MMP-2, MMP-9, and VEGF expres-
sion, resulting in inhibition of angiogenesis, invasion, and migra-
tion [20]. Moreover, a range of studies have reported that the
functions of FOXM1 in tumorigenesis can be regulated by miRNAs.
For example, downregulated miR-370 contributes to proliferation
and cellular senescence by up-regulating FOXM1 in acute myeloid
leukemia (AML) [2]. In our study, we found that the FOXM1 mRNA
X.-r. Li et al. / FEBS Letters 588 (2014) 3298–3307 330730UTR has miR-342-3p seed sequence binding sites by using pre-
diction tools. In the luciferase reporter assay, qRT-PCR andWestern
blot conﬁrmed the direct interaction between the FOXM1 mRNA
30UTR and miR-342-3p in HeLa and C33A human cervical cancer
cell lines.
EVL belongs to the Ena/VASP (Enabled/vasodilator-stimulated
phosphoprotein) family of proteins [Mena (mammalian Ena), VASP
and EVL], which have a range of roles in regulating the actin cyto-
skeleton. Grady et al. report that expression of EVL is commonly
suppressed in human colorectal cancer. And their results indicate
that the mechanism of silencing is CpG island methylation
upstream of EVL [14]. However, Hu et al. suggested EVL expression
level was higher in breast tumors compared to normal tissues and
its up-regulation was positively associated with the clinical stages
of breast cancer [21]. There was also reports indicated the elevated
expression levels of EVL in human glioblastoma multiforme [22].
Our study demonstrates the expression levels of the EVL mRNA
were generally reduced in cervical cancer tissues compared to
those in adjacent normal tissues. We speculate the different
expression level of EVL may attribute to the tissues speciﬁc in dif-
ferent human tumors. Of course, our group will focus on the
expression of EVL gene in other kind of tumors in the further study.
Accumulating evidence suggests that miRNAs play important
roles in both normal cellular identity and in the pathological state,
especially in tumorigenesis [23]. Among them, various miRNAs,
which acts as oncogenes or tumor suppressors, have been reported
to be associated with human cervical cancer. By comparing miRNA
expression in normal and cervical cancer tissues, 34 upregulated
miRNAs (onco-miRs) and 25 downregulated miRNAs (tumor sup-
pressor miRs) have been found by microarray and qRT-PCR [10].
Speciﬁcally, miR-21 is overexpressed and is a negative regulator
of CCL20. Overexpression of CCL20 suppresses differentiation and
nodular metastasis, and thus, miR-21 binding to the CCL20 30UTR
promotes malignancy [11]. Meanwhile, many miRNAs are down-
regulated in cervical cancer and act as tumor suppressors. The
Cui group evaluated cell growth and apoptosis in cervical cancer
cells through an MTT assay and ﬂow cytometry and found that
overexpression of miR-125b inhibited cell proliferation, induced
apoptosis, and reduced tumorigenicity by targeting the phosphoin-
ositide 3-kinase catalytic subunit delta (PIK3CD) through regula-
tion of the PI3K/Akt/mTOR signaling pathway [24]. However, we
revealed that miR-342-3p was down-regulated in human cervical
cell lines and inhibited proliferation, growth, invasion and migra-
tion through targeting FOXM1, which is up-regulated in cervical
intraepithelial neoplasia (CIN) tissues, cervical cancer tissues and
cell lines. The degree of up-regulation of FOXM1 was directly asso-
ciated with the CIN grade and cancer, and FOXM1 is negatively cor-
related with miR-342-3p. Moreover, miR-342 has been reported to
be an intronic miRNA, and the host gene is EVL in multiple mye-
loma. Intronic miRNAs and host genes are regulated dependently
and may contribute to the understanding of their biological roles
in cancer [25]. In our research, we conﬁrmed that the expression
of miR-342-3p was identical with its host gene, EVL, which is also
down-regulated in CIN as well as cervical cancer tissues and is neg-
atively correlated with FOXM1. Furthermore, we performed rescue
experiments through MTT assays, colony formation and invasion
and migration assays. The data indicate that FOXM1 could rescue
the suppression effects on proliferation, growth, invasion and
migration induced bymiR-342-3p in HeLa and C33A cells, elucidat-
ing that miR-342-3p acts as a tumor suppressor through FOXM1.
In summary, FOXM1 was predicted to be a target of miR-342-
3p, an intronic RNA of EVL. The luciferase reporter assay, qRT-
PCR and Western blot conﬁrmed this direct interaction. Moreover,
miR-342-3p suppressed the proliferation, growth, invasion and
migration in HeLa and C33A cells. The rescue experiments con-
ﬁrmed that FOXM1 is a direct functional target of miR-342-3p(Fig. 6D). Finally, miR-342-3p, corresponding with its host gene,
EVL, is down-regulated in CIN and cervical cancer tissues. miR-
342-3p and EVL are negatively correlated with FOXM1, which is
a response to the grade of CIN and cervical cancer.
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